EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The role of the primitive marker CD133 in CD34 ‐negative acute myeloid leukemia for the detection of leukemia stem cells

Tom Reuvekamp iD, Luca L G Janssen, Lok Lam Ngai, Jannemieke Carbaat-Ham, Daphne den Hartog, Willemijn J Scholten, Angèle Kelder, Diana Hanekamp, Eliza Wensink, Noortje van Gils, Patrycja Gradowska, Bob Löwenberg und 6 weitere

Cytometry Part B: Clinical Cytometry · 2025

DOI: 10.1002/cyto.b.22201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2025. Verfasst von Tom Reuvekamp und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: AC133 Antigen, Leukemia, Myeloid, Acute, Neoplastic Stem Cells, Antigens, CD34. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The most important reason for dismal outcomes in acute myeloid leukemia (AML) is the development of relapse. Leukemia stem cells (LSCs) are hypothesized to initiate relapse, and high CD34+CD38− LSC load is associated with poor prognosis. In 10% of AML patients, CD34 is not or is low expressed on the leukemic cells (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AC133 AntigenLeukemia, Myeloid, AcuteNeoplastic Stem CellsAntigens, CD34Biomarkers, TumorHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedPrognosisADP-ribosyl Cyclase 1Flow Cytometry

Stichwörter der Autor:innen

CD133acute myeloid leukemiaflow cytometryleukemia stem cellsmeasurable residual disease

Substanzen

AC133 AntigenAntigens, CD34Biomarkers, TumorPROM1 protein, humanADP-ribosyl Cyclase 1

Autor:innen und Institutionen

  • Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
  • Department of Hematology, Amsterdam UMC location Universiteit van Amsterdam, Amsterdam, The Netherlands.
  • Department of Hematology, Erasmus MC Cancer Institute and University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC location Universiteit van Amsterdam, Amsterdam, The Netherlands.
  • HOVON Foundation, Rotterdam, The Netherlands.

ORCID-Profile: Tom Reuvekamp, Costa Bachas, Jacqueline Cloos

Zitieren

APA

Reuvekamp, T., Janssen, L. L. G., Ngai, L. L., Carbaat-Ham, J., den Hartog, D., Scholten, W. J., Kelder, A., Hanekamp, D., Wensink, E., van Gils, N., Gradowska, P., Löwenberg, B., Ossenkoppele, G. J., van de Loosdrecht, A. A., Westers, T. M., Smit, L., Bachas, C., & Cloos, J. (2025). The role of the primitive marker CD133 in CD34 ‐negative acute myeloid leukemia for the detection of leukemia stem cells. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22201

Vancouver

Reuvekamp T, Janssen LLG, Ngai LL, Carbaat-Ham J, den Hartog D, Scholten WJ, et al. The role of the primitive marker CD133 in CD34 ‐negative acute myeloid leukemia for the detection of leukemia stem cells. Cytometry Part B: Clinical Cytometry. 2025. doi:10.1002/cyto.b.22201

BibTeX
@article{Reuvekamp2025,
  author = {Reuvekamp, Tom and Janssen, Luca L G and Ngai, Lok Lam and Carbaat-Ham, Jannemieke and den Hartog, Daphne and Scholten, Willemijn J and Kelder, Angèle and Hanekamp, Diana and Wensink, Eliza and van Gils, Noortje and Gradowska, Patrycja and Löwenberg, Bob and Ossenkoppele, Gert J and van de Loosdrecht, Arjan A and Westers, Theresia M and Smit, Linda and Bachas, Costa and Cloos, Jacqueline},
  title = {The role of the primitive marker CD133 in CD34 ‐negative acute myeloid leukemia for the detection of leukemia stem cells},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2025},
  doi = {10.1002/cyto.b.22201}
}
Kostenlos starten →